Economic Considerations in Alzheimer's Disease

@article{Meek1998EconomicCI,
  title={Economic Considerations in Alzheimer's Disease},
  author={Patrick D. Meek and E. Kristin McKeithan and Glen T. Schumock},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={1998},
  volume={18}
}
Alzheimer's disease (AD) is the third most expensive disease in the United States, costing society approximately $100 billion each year. It is one of the most prevalent illnesses in the elderly population, and with the aging of society, will become even more significant. Costs associated with AD include direct medical costs such as nursing home care, direct nonmedical costs such as in‐home day care, and indirect costs such as lost patient and caregiver productivity. Medical treatment may have… 
View on Wiley
ncbi.nlm.nih.gov
193 Citations
Highly Influential Citations
6
Background Citations
57
Methods Citations
1

193 Citations

Citation Type

Citation Type

Economic considerations in the management of Alzheimer’s disease
  • C. Zhu, M. Sano
  • Medicine, Political Science
    Clinical interventions in aging
  • 2006
Alzheimer’s disease is a devastating chronic disease that significantly increases healthcare costs and affects the quality of life (QoL) of the afflicted patients and their caregivers. Population…
The economic cost of Alzheimer's disease: Family or public health burden?
TLDR
Dementia should be the focus of analysis when public health policies are being devised and more local evidence is gathered about the burden of AD and how it can be shaped by treatment options.
The pharmacoeconomics of Alzheimer's disease.
  • H. Fillit
  • Medicine, Political Science
    The American journal of managed care
  • 2000
Alzheimer's disease (AD), the leading cause of disability in people older than 75 years of age, has direct and indirect medical costs estimated at $100 billion per year. Yet underdiagnosis, coding,…
The Impact of Symptom Severity on the Cost of Alzheimer's Disease
TLDR
The direct and indirect costs of AD are considerably lower for patients with fewer symptoms, and longitudinal studies will determine the impact on the overall cost of care of interventions that reduce symptoms and maintain patients at earlier stages of the disease.
Managed care decisions in Alzheimer's disease.
  • H. Fillit
  • Medicine
    The American journal of managed care
  • 2000
TLDR
Key areas of AD care improvement include protocol-driven diagnosis, referral, and treatment; education of primary care physicians and caregivers; development of an integrated case management approach; and use of validated measures to assess outcomes.
[Economic impact of Alzheimer's Disease in Brazil: is it possible to improve care and minimize costs?].
TLDR
The literature proposes the adoption of models of care that maximize the functional independence of the elderly and maintain their skills, such as Day Care Centers for the Elderly and rehabilitation programs and support offered toThe elderly and their family members.
Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective.
TLDR
There is a growing body of evidence to support the inclusion of this and other therapies into an MCO's AD treatment armamentarium, and opportunities exist through patient management programs targeted toward early diagnosis, effective use of medications, control of comorbidities, and patient and family support to partially offset these costs while providing quality patient care.
Health State Values for Use in the Economic Evaluation of Treatments for Alzheimer’s Disease
TLDR
The literature on health state values in AD is limited and overly reliant on a single symptom (cognition) to describe disease progression, and other approaches to characterizing disease progression in AD based on multiple outcomes or dependency may be better predictors of costs and utilities in economic evaluations.
Family or public-health burden?
TLDR
South American countries should strengthen their policy and planning capabilities by gathering more local evidence about the burden of AD and how it can be shaped by treatment options.
Reduction of Caregiver Burden in Alzheimer's Disease by Treatment with Galantamine
TLDR
The literature on caregiver burden, the components of caregIVER burden, effects of caregiving on the health of caregivers, the cost of Alzheimer's disease on the caregiver and society, and the benefits attainable with treatment are reviewed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
The economic burden of Alzheimer's disease care.
TLDR
With projected increases in the number of persons at risk of developing Alzheimer's disease, the economic impact of the disease on future long-term care costs will be significant.
The economic impact of the tacrine in the treatment of Alzheimer's disease.
The economic cost of senile dementia in the United States, 1985.
TLDR
This paper attempts to estimate various costs associated with the care of senile dementia, based on available secondary data, using the direct cost and indirect cost approach and avoided double counting to identify the additional economic costs due toSenile dementia.
The economic cost of senile dementia in the United States, 1985.
TLDR
This paper attempts to estimate various costs associated with the care of senile dementia, based on available secondary data, using the direct cost and indirect cost approach and avoided double counting to identify the additional economic costs due to seniles dementia.
Estimated prevalence of Alzheimer's disease in the United States.
  • D. Evans
  • Psychology
    The Milbank quarterly
  • 1990
TLDR
Limitations on these estimates notwithstanding, the projections indicate that more studies are needed to identify the etiology of Alzheimer's disease, its incidence, and the future costs of relevant institutional and community care.
The US economic and social costs of Alzheimer's disease revisited.
TLDR
New national prevalence estimates of the economic and social costs of Alzheimer's disease are presented and the estimated discounted present values of the direct and total costs of all current and future generations of Alzheimer’s patients are $536 billion and $1.75 trillion.
The costs of family contributions to the care of persons with dementia.
TLDR
Total care costs rise by $1,158 for each additional dependency in an activity of daily living (ADL), while reliance on paid services is 5% higher for eachAdditional $10,000 household income and drops by 25% if the patient lives in the caregiver's household.
Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.
TLDR
The data suggest that clinically diagnosed Alzheimer's disease is a common condition and that its public health impact will continue to increase with increasing longevity of the population.
Caregiver time use: An outcome measure in clinical trial research on Alzheimer's disease
The impact of dementia on the family.
TLDR
Patients suffering from an irreversible dementia reported disturbances of patient behavior such as catastrophic reactions, waking at night, suspiciousness, and communication disorders, some of which can be alleviated by physician-initiated intervention.
...
1
2
...